Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide and Carboplatin in Recurrent Glioblastoma
NCT00014105Phase 2Unknown
- Sponsor
- Atlantic Health System
- Start
- Dec 2000
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide and carboplatin in glioblastoma multiforme (GBM), sponsored by Atlantic Health System. Primary endpoint: Maximum Tolerated Dose. Status: unknown.
02
Drugs
temozolomidecarboplatin
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00014105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00014105.